Nasopharyngeal Carcinoma (NPC) Axitinib
This is an open-label, single arm, phase 2 clinical trial evaluating the activity and safety of single-agent axitinib in recurrent or metastatic NPC patients who failed at least one line of platinum based chemotherapy.
Recurrent or Metastatic NPC
DRUG: axitinib
To evaluate the efficacy (clinical benefit rate) of single-agent axitinib in patients with recurrent or metastatic NPC, and its impact on disease progression., 3 years
To assess objective response rate, 3 years|To assess duration of response, 3 years|To assess progression-free survival, 3 Years|To assess overall survival, 3 Years|To evaluate the safety and tolerability of axitinib, 3 years|To evaluate axitinib plasma pharmacokinetics and to correlate these plasma concentrations with efficacy and safety parameters, 3 years|To study blood and tissue biomarkers and correlate with cancer- and treatment-related outcomes, 3 years
This is an open-label, single arm, phase 2 clinical trial evaluating the activity and safety of single-agent axitinib in recurrent or metastatic NPC patients who failed at least one line of platinum based chemotherapy.